Terms: = Leukemia AND REL, I-Rel, 5966, ENSG00000162924, C-Rel AND Prognosis
16 results:
1. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.
Russler-Germain DA; Krysiak K; Ramirez C; Mosior M; Watkins MP; Gomez F; Skidmore ZL; Trani L; Gao F; Geyer S; Cashen AF; Mehta-Shah N; Kahl BS; Bartlett NL; Alderuccio JP; Lossos IS; Ondrejka SL; Hsi ED; Martin P; Leonard JP; Griffith M; Griffith OL; Fehniger TA
Blood Adv; 2023 Sep; 7(18):5524-5539. PubMed ID: 37493986
[TBL] [Abstract] [Full Text] [Related]
2. Refining prognosis in chronic lymphocytic leukemia with normal Fluorescence in situ hybridization results.
Avenarius MR; Huang Y; Hyak J; Byrd JC; Bhat SA; Grever M; Kittai AS; Rogers KA; Jones D; Zhao W; Heerema NA; Abruzzo LV; Woyach J; Miller CR
Hematol Oncol; 2023 Oct; 41(4):771-775. PubMed ID: 37010242
[TBL] [Abstract] [Full Text] [Related]
3. Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma.
Furqan F; Ahn KW; Chen Y; Kaur M; Abutalib SA; Ahmed N; Ahmed S; Kharfan-Dabaja MA; Friedberg J; Gregory T; Hill L; Sterling C; Barta SK; Shadman M; Perales MA; Zain J; Herrera AF; Sauter C; Hamadani M
Br J Haematol; 2023 Jan; 200(1):54-63. PubMed ID: 36120837
[TBL] [Abstract] [Full Text] [Related]
4. An alternative CYB5A transcript is expressed in aneuploid ALL and enriched in relapse.
Bartsch L; Schroeder MP; Hänzelmann S; Bastian L; Lázaro-Navarro J; Schlee C; Tanchez JO; Schulze V; Isaakidis K; Rieger MA; Gökbuget N; Eckert C; Serve H; Horstmann M; Schrappe M; Brüggemann M; Baldus CD; Neumann M
BMC Genom Data; 2022 Apr; 23(1):30. PubMed ID: 35436854
[TBL] [Abstract] [Full Text] [Related]
5. A novel approach for relapsed/refractory FLT3
Li KX; Wu HY; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Yang DH; Huang YX
Mol Cancer; 2022 Mar; 21(1):66. PubMed ID: 35246156
[TBL] [Abstract] [Full Text] [Related]
6. Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network.
Zappasodi P; Marbello L; Borlenghi E; Fumagalli M; Bernardi M; Fracchiolla N; Mancini V; Da Vià M; Ravano E; Cerqui E; Ferretti VV; Rocca B; Calvello C; Cazzola M; Castagnola C; Rossi G
Ann Hematol; 2018 Nov; 97(11):2107-2115. PubMed ID: 30009341
[TBL] [Abstract] [Full Text] [Related]
7. Screening of prognostic risk microRNAs for acute myeloid leukemia.
Gao HY; Wang W; Luo XG; Jiang YF; He X; Xu P; Chen X; Li XY
Hematology; 2018 Dec; 23(10):747-755. PubMed ID: 29781401
[TBL] [Abstract] [Full Text] [Related]
8. Emerging resistant bacteria strains in bloodstream infections of acute leukaemia patients: results of a prospective study by the Rete Ematologica Lombarda (rel).
Cattaneo C; Zappasodi P; Mancini V; Annaloro C; Pavesi F; Skert C; Ferrario A; Todisco E; Saccà V; Verga L; Passi A; Da Vià M; Ferrari S; Mometto G; Petullà M; Nosari A; Rossi G
Ann Hematol; 2016 Dec; 95(12):1955-1963. PubMed ID: 27650830
[TBL] [Abstract] [Full Text] [Related]
9. Integrative genomic analyses of the RNA-binding protein, RNPC1, and its potential role in cancer prediction.
Ding Z; Yang HW; Xia TS; Wang B; Ding Q
Int J Mol Med; 2015 Aug; 36(2):473-84. PubMed ID: 26046131
[TBL] [Abstract] [Full Text] [Related]
10. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
[TBL] [Abstract] [Full Text] [Related]
11. Interferon regulatory factor-4 activates IL-2 and IL-4 promoters in cooperation with c-rel.
Shindo H; Yasui K; Yamamoto K; Honma K; Yui K; Kohno T; Ma Y; Chua KJ; Kubo Y; Aihara H; Ito T; Nagayasu T; Matsuyama T; Hayashi H
Cytokine; 2011 Dec; 56(3):564-72. PubMed ID: 21890374
[TBL] [Abstract] [Full Text] [Related]
12. Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia.
Rinaldi A; Mian M; Kwee I; Rossi D; Deambrogi C; Mensah AA; Forconi F; Spina V; Cencini E; Drandi D; Ladetto M; Santachiara R; Marasca R; Gattei V; Cavalli F; Zucca E; Gaidano G; Bertoni F
Br J Haematol; 2011 Sep; 154(5):590-9. PubMed ID: 21749360
[TBL] [Abstract] [Full Text] [Related]
13. Gain of the short arm of chromosome 2 (2p) is a frequent recurring chromosome aberration in untreated chronic lymphocytic leukemia (CLL) at advanced stages.
Chapiro E; Leporrier N; Radford-Weiss I; Bastard C; Mossafa H; Leroux D; Tigaud I; De Braekeleer M; Terré C; Brizard F; Callet-Bauchu E; Struski S; Veronese L; Fert-Ferrer S; Taviaux S; Lesty C; Davi F; Merle-Béral H; Bernard OA; Sutton L; Raynaud SD; Nguyen-Khac F
Leuk Res; 2010 Jan; 34(1):63-8. PubMed ID: 19406473
[TBL] [Abstract] [Full Text] [Related]
14. Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma.
Nasr R; El-Sabban ME; Karam JA; Dbaibo G; Kfoury Y; Arnulf B; Lepelletier Y; Bex F; de Thé H; Hermine O; Bazarbachi A
Oncogene; 2005 Jan; 24(3):419-30. PubMed ID: 15543232
[TBL] [Abstract] [Full Text] [Related]
15. Constitutive NF-kappab/rel activation in philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).
Munzert G; Kirchner D; Ottmann O; Bergmann L; Schmid RM
Leuk Lymphoma; 2004 Jun; 45(6):1181-4. PubMed ID: 15359998
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic significance of the heterogenous expression of IgG Fc receptors in B-cell chronic lymphocytic leukemia.
Schranz V; Gráf F
Ann Hematol; 1992 Mar; 64(3):140-5. PubMed ID: 1571409
[TBL] [Abstract] [Full Text] [Related]
